]> 2026-04-12T04:14:14-07:00 Next-Generation CAR T-Cell Therapy for GBM 0 en Includes expected side effects such as fevers and altered mental status post-infusion, with significant neurotoxicity that has been manageable in initial patients. 2025-01-18T08:25:50Z 2460693.8512732 Next-Generation CAR T-Cell Therapy for GBM 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","Introduces a novel, highly personalized approach targeting mixed cell populations within GBM tumors. Early results demonstrate potential for substantial impact on tumor reduction and patient outcomes, indicating a promising direction for future GBM treatment strategies."] Next-Generation CAR T-Cell Therapy for GBM# ERR0de0b09fdf871942cb9b8a10a8978dce 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Recent advancements in CAR T-cell therapy, particularly the innovative approach taken in the INCIPIENT trial, have shown promising early results for treating GBM. By targeting mixed cell populations within tumors and observing dramatic reductions in tumor size, this therapy represents a potential breakthrough in GBM treatment. While further research is needed to understand long-term effectiveness and manage side effects, these early findings provide hope for more effective GBM therapies.\nBen Williams book: Chimeric antigen receptor (CAR) T-cells are T-cells that have been genetically engineered,\ncommonly by the use of a retroviral vector, to express artificial receptors specifically\ntargeted to a chosen tumor-associated or tumor-specific antigen. CAR T-cells directed to\nCD19 have been used with impressive success for B-cell acute lymphoblastic leukemia\n(ALL), and tisagenlecleucel, an anti-CD19 CAR T-cell therapy was approved for this\nindication on August 30, 2017. For glioblastoma, phase 1 CAR T-cell trials are currently\nactive, with preliminary outcomes now published for two of these trials, as discussed\nbelow."] Next-Generation CAR T-Cell Therapy for GBM# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name